Viral kinetic of HCV genotype‐4 during pegylated interferon alpha 2a: ribavirin therapy

Moutaz Derbala(Weill Cornell Medical College in Qatar), M. A. Al Khinji(Weill Cornell Medical College in Qatar), A. D. Al‐Marri, M. Al Mohanadi(Hamad Medical Corporation), Fatma M. Shebl(University of Maryland, Baltimore), Anil John(University of Benin), Saad Rashid Al Kaabi(Hamad Medical Corporation), N. Z. El Dweik(Hamad Medical Corporation), Abdülbari Bener, M. T. Butt(Hamad General Hospital), R. Yakoob(Hamad Medical Corporation), A. M. Amer
Journal of Viral Hepatitis
May 15, 2008
10.1111/j.1365-2893.2008.00988.x
Cited by 16

Related Papers

Artificial intelligence in medical education - perception among medical students
|BMC Medical Education|2024|121
Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
|Lara D. Veeken|2012|106
Factors predicting successful outcome following neostigmine therapy in acute colonic pseudo‐obstruction: A prospective study
|Journal of Gastroenterology and Hepatology|2005|73
The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole
|Annals of Tropical Medicine and Parasitology|2002|40
Two-year follow-up of the microfilaraemia of asymptomatic brugian filariasis, after treatment with two, annual, single doses of ivermectin, diethylcarbamazine and albendazole, in various combinations
|Annals of Tropical Medicine and Parasitology|2000|39